Clinical Efficacy And Adverse Reactions Of Pirfennidone In Treatment Of Idiopathic Pulmonary

AIM To investigate the clinical efficacy and adverse reactions of pirfenidone in the treatment of idiopathic pulmonary fibrosis（IPF）.METHODSForty patients with IPF in stable phase were divided into control group and trial group,20 cases in each group.The control group was given antitussive,antiasthma and other symptomatic treatment.One the basis of symptomatic treatment,the trial group was given pirfenidone capsules,0.4g,orally,three times daily for 48 weeks.The levels of forced vital capacity（FVC）,forced expiratory volume in 1 second（FEV₁）and diffusing capacity of carbon monoxide(DL_CO)were recorded before and after treatment.And the adverse reactions were observed.RESULTS Before the treatment,there were no significant differences in FVC,FEV₁ and DLco between the two groups（P>0.05）.After treatment,there were no significant differences in FVC between the two groups at the end of 12,24 and 36 week（P>0.05）.The FVC in the control group was lower than that of the trial group（（2.31?0.93）L vs.（2.86?0.78）L,P<0.05）at the end of 48week.At the end of 12,24,36 and 48 week,the FEV₁ in the control group was lower than that in the trial group（P<0.05）,but no significant difference was found in DL_COO between two groups（P>0.05）.However,the decline trend of the DL_COO in the trial group was relatively slow.The incidence of adverse reaction in the trial group was 65%（13/20）.The adverse reaction was mostly photosensitive reaction,loss of appetite,abdominal discomfort and burnout,which was mild to moderate,and the patients were tolerant.CONCLUSION Pirfenidone is efficacy in treating IPF and well tolerated.